A real-world, triple-cohort study on the effectiveness and safety of telitacicept in immunosuppressant-naïve and refractory lupus nephritis

Suren Lai, Shanshan Li, Jiaying Cai, Lingyun Sun, Huasang Huang, Jie Wang, Jinhai Chen, Shizhong Shen · 2026

Read A real-world, triple-cohort study on the effectiveness and safety of telitacicept in immunosuppressant-naïve and refractory lupus nephritis by Suren Lai, Shanshan Li, Jiaying Cai, Lingyun Sun, Huasang Huang, Jie Wang, Jinhai Chen, Shizhong Shen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13623623.txt.

Description

Suren Lai and seven co-authors report real-world results for telitacicept, a B-cell drug, in lupus nephritis, in a study published in two thousand twenty-six. The kidney disease flares when the immune system attacks the kidneys. Three groups were compared at two centers: new patients given the drug plus standard care, new patients on standard care alone, and hard-to-treat patients given the drug as an add-on. Fifty-five patients took part.

New patients on the drug reached full remission a bit sooner than those on standard care alone, though the gap was not firm. Both drug groups showed better kidney blood tests and needed less steroid. New patients answered better than the hard-to-treat group, hinting that early use helps most. Infections were the main side effect and stayed mild to moderate.

Catalog record

CREATORSuren Lai, Shanshan Li, Jiaying Cai, Lingyun Sun, Huasang Huang, Jie Wang, Jinhai Chen, Shizhong Shen
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE29 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13623623

Browse the full library · About the Tower of Babel